Neuroscience Companies in North America

Verge Genomics is a next-generation biopharmaceutical start-up using systems biology to accelerate development of life-saving treatments for neurodegenerative diseases. Our platform uses patient genomes, gene expression, and epigenomics to identify new therapeutic gene targets, predict effective drugs, and stratify patient subpopulations for increased clinical success. Verge's approach offers a breakthrough opportunity to identify drugs that dramatically improve patient outcomes and fundamentally lower the cost curve of pharmaceutical development. We are looking for extraordinary individuals to join our motivated team in taking on our generation’s biggest healthcare challenges: ALS, Parkinson’s Disease, and Alzheimer's Disease. Our employees are our most important asset; we are a team of founders, excited to learn, roll up our sleeves, and make a real impact. The startup nature of Verge Genomics provides multiple growth opportunities into other areas of the company. As one of the early employees at Verge, your work will have a direct impact on the foundation of a groundbreaking new drug development model. In addition to competitive compensation and benefits, we offer perks like unlimited vacation/sick days, on-site gym access, and free lunch. Verge actively seeks a diverse applicant pool in order to build the strongest possible workforce. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.

Imaginostics is a health tech startup developing magnetic resonance imaging (MRI) technology, with locations in Cambridge, MA and Lake Nona, FL. We are developing non-invasive diagnostic solutions for renal-safe vascular angiography and breakthrough quantitative imaging biomarkers that can provide new insight into health and disease. We have a nimble, innovative, and growing team that embraces a bold vision to take breakthroughs in magnetic resonance imaging and transform them into a platform that can improve lives. Our proprietary QUTE-CE MRI methodology can non-invasively assay vascular structure, function, and leakage in high resolution anywhere in the body at the single-patient level, providing scientific and clinical researchers new endpoints for early detection and enhanced characterization of complex diseases. Data can be used to visualize the vasculature, assay health and disease, stratify research populations, support early preventative diagnostics, and help assess drug efficacy. We also provide biomarker solutions commercially through CROs to pharma and participate in pre-clinical and clinical research in a variety of focus areas collaborating with world-renowned researchers at leading institutions. Our technology and software are compatible with existing MRI scanners. Imaginostics’ research / development focus areas include: • Safe Full Body Vascular Enhanced Imaging for Renally Impaired Groups • Neurological Drug Characterization (Vascular Function, Density and Structure) • Biomarkers for Alzheimer’s Disease and Related Dementias (ADRD) • Traumatic Brain Injury (TBI) • Cardiovascular Biomarkers • Kidney Biomarkers Please reach out if you would like to explore opportunities to work together: • Pharmaceutical Companies • Hospitals • Academic Research Collaborators • Investors • Engineers and Researchers (please see current openings) To learn more, please visit: http://www.imaginostics.com

Better data. Better brains. Kernel is developing the world’s most comprehensive library of brain-based biomarkers and applying them to develop new treatments, improve patient care, and optimize brain function.

NerveX develops intelligent neuromodulation devices to repair and augment the nervous system

Neuralink is a team of exceptionally talented people. We are creating the future of brain-machine interfaces: building devices now that will help people with paralysis and inventing new technologies that will expand our abilities, our community, and our world. Our goal is to build a system with at least two orders of magnitude more communication channels (electrodes) than current clinically-approved devices. This system needs to be safe, it must have fully wireless communication through the skin, and it has to be ready for patients to take home and use on their own. Our device, called the Link, will be able to record from 1024 electrodes and is designed to meet these criteria.